Fig. 6

Viral dose dependent transduction effect with BX795 treatment. a The percentage of double transduced cells with LdCK-GFP MOI 10, and CAR-TEV-mCherry MOI 5, 10, and 20, in the absence or presence of BX795. Data are the average of four experiments done with cells from two donors. b The percentage of double transduced cells with LdCK MOI 10, and MSLN CAR-TEV MOI 2.5, 5, 10, and 20, in the absence or presence of BX795. Data from one representative donor. c, d Virus dose-escalation for MSLN CAR-TEV transduction in human primary T cells in the absence or presence of BX795. Data from one representative donor